A Phase 2 interventional study of Tadalafil 2.5 mg and Tadalafil 5 mg in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 6 sites in Japan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2011-03-29.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 2, and was the 5th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 422 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 5 in phase 2, and was the 5th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the long-term safety and efficacy of tadalafil in Japanese men with signs and symptoms of benign prostatic hyperplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
Drug: Tadalafil 2.5 mg
5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
Drug: Tadalafil 5 mg
Placebo tablet taken by mouth once a day for 12 weeks. Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.
Drug: Placebo
oral, daily
Also known as: LY450190, Cialis
oral, daily
Also known as: LY450190, Cialis
oral, daily
Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint
IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
Time frame: Baseline, 12 weeks
Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint
Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Time frame: Baseline, 12 weeks
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint
The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.
Time frame: Baseline, 12 weeks
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint
Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).
Time frame: Baseline, 12 weeks
Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement
Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.
Time frame: Baseline, 12 weeks
Number of Participants With Adverse Events During 12 Weeks of the Study
A listing of Adverse Events are reported in the Reported Adverse Event Section.
Time frame: Baseline through 12 weeks
Change From Baseline in Blood Pressure at 12-Week Endpoint
Time frame: Baseline, 12 weeks
Change From Baseline in Sitting Heart Rate at 12-Week Endpoint
Time frame: Baseline, 12 Weeks
Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint
Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.
Time frame: Baseline, 12 weeks
Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint
Measurement of nanograms of PSA per milliliter (ng/mL) of blood.
Time frame: Baseline, 12 weeks
Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Time frame: Baseline, 54 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint
IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
Time frame: Baseline, 54 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
Time frame: Baseline, 54 weeks
Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint
Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Time frame: Baseline, 54 weeks
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint
The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.
Time frame: Baseline, 54 weeks
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint
Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).
Time frame: Baseline, 54 weeks
Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment
A listing of Adverse Events are reported in the Reported Adverse Event Section.
Time frame: End of 12 weeks of double-blind through 54 weeks
Change From Baseline in Blood Pressure During at 54-Week Endpoint
Time frame: Baseline, 54 weeks
Change From Baseline in Sitting Heart Rate at 54-Week Endpoint
Time frame: Baseline, 54-weeks
Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint
Measurement of nanograms of PSA per milliliter (ng/mL) of blood.
Time frame: Baseline, 54 weeks
Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint
Post residual volume (PVR) is measured by ultrasound at regular intervals.
Time frame: Baseline, 54 weeks
| Milestone | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Started | 142 | 140 | 140 |
| Completed | 135 | 128 | 131 |
| Not completed | 7 | 12 | 9 |
| Withdrew: Adverse event | 4 | 5 | 5 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 |
| Milestone | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Started | 135 | 128 | 131 |
| Completed | 113 | 109 | 101 |
| Not completed | 22 | 19 | 30 |
| Withdrew: Adverse event | 12 | 7 | 16 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Protocol violation | 4 | 5 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 | 3 |
| Withdrew: Physician decision | 4 | 2 | 3 |
| Withdrew: Lack of efficacy | 1 | 4 | 0 |
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint | -4.5 ± 0.4 | -4.9 ± 0.4 | -3.8 ± 0.4 |
IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint | -1.6 ± 0.2 | -1.6 ± 0.2 | -1.4 ± 0.2 |
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint | -2.9 ± 0.3 | -3.3 ± 0.3 | -2.4 ± 0.3 |
Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint | -0.5 ± 0.1 | -0.7 ± 0.1 | -0.4 ± 0.1 |
The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint | -0.7 ± 0.1 | -0.8 ± 0.1 | -0.7 ± 0.1 |
Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).
| milliliters per second | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint | 0.7 ± 0.3 | 0.6 ± 0.3 | 1.4 ± 0.3 |
Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.
| nanogram/milliliter | Tadalafil 2.5 mg | Tadalafil 5 mg |
|---|---|---|
| 0-6 hours (n=225, 200) | 86.0 ± 44.0 | 169 ± 41.2 |
| 6-12 hours (n=72, 72) | 68.7 ± 37.6 | 140 ± 51.3 |
| 12-24 hours (n=102, 106) | 57.5 ± 49.1 | 93.6 ± 55.6 |
| 24-48 hours (n=11, 8) | 43.5 ± 89.7 | 75.2 ± 56.0 |
A listing of Adverse Events are reported in the Reported Adverse Event Section.
| participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Serious Adverse Events | 2 | 2 | 1 |
| Non-Serious Adverse Events | 52 | 54 | 53 |
| mmHg | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Systolic Blood Pressure | -2.0 ± 11.9 | -3.4 ± 12.2 | -0.5 ± 14.0 |
| Diastolic Blood Pressure | -0.7 ± 9.5 | -2.9 ± 8.3 | -0.9 ± 10.1 |
| beats per minute | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Heart Rate at 12-Week Endpoint | -0.7 ± 9.9 | -1.2 ± 9.8 | 0.0 ± 8.2 |
Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.
| milliliters | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint | -9.41 ± 41.43 | -5.15 ± 40.32 | -4.72 ± 36.40 |
Measurement of nanograms of PSA per milliliter (ng/mL) of blood.
| Micrograms per liter | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint | 0.26 ± 1.54 | 0.09 ± 0.88 | 0.14 ± 2.90 |
The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint | -5.2 ± 5.9 | -5.4 ± 6.3 | -6.2 ± 5.4 |
IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint | -1.9 ± 2.5 | -1.6 ± 2.8 | -1.8 ± 2.5 |
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint | -3.4 ± 4.1 | -3.7 ± 4.5 | -4.3 ± 3.9 |
Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint | -0.8 ± 1.2 | -1.0 ± 1.4 | -0.9 ± 1.4 |
The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint | -0.9 ± 2.0 | -1.0 ± 2.4 | -0.9 ± 2.0 |
Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).
| units on a scale | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint | 2.29 ± 4.29 | 1.51 ± 4.48 | 2.01 ± 5.05 |
A listing of Adverse Events are reported in the Reported Adverse Event Section.
| participants | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Serious Adverse Events | 3 | 4 | 4 |
| Non-Serious Adverse Events | 81 | 81 | 94 |
| millimeters of mercury (mmHg) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Systolic blood pressure | -2.1 ± 13.4 | -1.2 ± 13.2 | -0.5 ± 14.2 |
| Diastolic blood pressure | -1.6 ± 9.6 | -2.9 ± 9.2 | -1.3 ± 9.8 |
| beats per minute (bpm) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Heart Rate at 54-Week Endpoint | 1.4 ± 10.4 | 0.4 ± 9.3 | 2.1 ± 10.6 |
Measurement of nanograms of PSA per milliliter (ng/mL) of blood.
| microgram/liter | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint | 0.4 ± 1.0 | 0.3 ± 0.9 | 0.3 ± 1.4 |
Post residual volume (PVR) is measured by ultrasound at regular intervals.
| milliliter | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint | -5.7 ± 50.0 | -1.9 ± 42.9 | -5.5 ± 46.8 |
Collected over Treatment-emergent adverse events (TEAEs) - defined as events that 1st occurred/worsened after randomization at Week 0.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil 2.5 mg - Double-Blind Phase | — | 2/142 (1.4%) | 52/142 (36.6%) |
| Tadalafil 5 mg - Double-Blind Phase | — | 2/140 (1.4%) | 54/140 (38.6%) |
| Placebo - Double-Blind Phase | — | 1/140 (0.7%) | 53/140 (37.9%) |
| Tadalafil 2.5 mg: Tadalafil 5 mg Open-Label | — | 3/135 (2.2%) | 81/135 (60%) |
| Tadalafil 5 mg: Tadalafil 5 mg Open-Label | — | 4/128 (3.1%) | 81/128 (63.3%) |
| Placebo: Tadalafil 5 mg Open-Label | — | 4/131 (3.1%) | 94/131 (71.8%) |
| Event | Tadalafil 2.5 mg - Double-Blind Phase | Tadalafil 5 mg - Double-Blind Phase | Placebo - Double-Blind Phase | Tadalafil 2.5 mg: Tadalafil 5 mg Open-Label | Tadalafil 5 mg: Tadalafil 5 mg Open-Label | Placebo: Tadalafil 5 mg Open-Label |
|---|---|---|---|---|---|---|
| Jaw fractureInjury, poisoning and procedural complications | 0/142 | 0/140 | 0/140 | 0/135 | 1/128 | 0/131 |
| Traumatic arthritisInjury, poisoning and procedural complications | 0/142 | 0/140 | 0/140 | 0/135 | 1/128 | 0/131 |
| Back painMusculoskeletal and connective tissue disorders | 0/142 | 0/140 | 0/140 | 0/135 | 1/128 | 0/131 |
| Urinary retentionRenal and urinary disorders | 0/142 | 0/140 | 0/140 | 0/135 | 1/128 | 0/131 |
| Colonic polypGastrointestinal disorders | 0/142 | 0/140 | 0/140 | 0/135 | 0/128 | 1/131 |
| Jaundice cholestaticHepatobiliary disorders | 0/142 | 0/140 | 0/140 | 0/135 | 0/128 | 1/131 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/142 | 0/140 | 0/140 | 0/135 | 0/128 | 1/131 |
| Cerebral infarctionNervous system disorders | 0/142 | 0/140 | 0/140 | 0/135 | 0/128 | 1/131 |
| Subarachnoid haemorrhageNervous system disorders | 0/142 | 0/140 | 0/140 | 0/135 | 0/128 | 1/131 |
| Sudden hearing lossEar and labyrinth disorders | 0/142 | 0/140 | 0/140 | 1/135 | 0/128 | 0/131 |
| Event | Tadalafil 2.5 mg - Double-Blind Phase | Tadalafil 5 mg - Double-Blind Phase | Placebo - Double-Blind Phase | Tadalafil 2.5 mg: Tadalafil 5 mg Open-Label | Tadalafil 5 mg: Tadalafil 5 mg Open-Label | Placebo: Tadalafil 5 mg Open-Label |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/142 | 14/140 | 18/140 | 25/135 | 15/128 | 19/131 |
| DiarrhoeaGastrointestinal disorders | 3/142 | 2/140 | 5/140 | 8/135 | 11/128 | 12/131 |
| HeadacheNervous system disorders | 2/142 | 3/140 | 3/140 | 2/135 | 3/128 | 9/131 |
| Back painMusculoskeletal and connective tissue disorders | 2/142 | 2/140 | 2/140 | 5/135 | 5/128 | 8/131 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/142 | 1/140 | 2/140 | 1/135 | 2/128 | 7/131 |
| DyspepsiaGastrointestinal disorders | 2/142 | 4/140 | 0/140 | 4/135 | 6/128 | 5/131 |
| EczemaSkin and subcutaneous tissue disorders | 0/142 | 0/140 | 3/140 | 2/135 | 3/128 | 6/131 |
| Seasonal allergyImmune system disorders | 1/142 | 1/140 | 2/140 | 2/135 | 1/128 | 5/131 |
| GastritisGastrointestinal disorders | 2/142 | 2/140 | 2/140 | 5/135 | 2/128 | 3/131 |
| Reflux oesophagitisGastrointestinal disorders | 3/142 | 2/140 | 0/140 | 5/135 | 4/128 | 4/131 |
| Age Continuous(years) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 66.4 ± 7.4 | 66.9 ± 7.7 | 67.0 ± 6.9 | 66.8 ± 7.3 |
| Sex: Female, Male(Participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 142 | 140 | 140 | 422 |
| Race/Ethnicity, Customized(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Japanese | 142 | 140 | 140 | 422 |
| Region of Enrollment(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 142 | 140 | 140 | 422 |
| Baseline (Visit 3) Benign Prostatic Hyperplasia Severity(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Moderate | 100 | 102 | 100 | 302 |
| Severe | 42 | 38 | 40 | 120 |
| Current Alcohol Use(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Yes | 96 | 92 | 93 | 281 |
| No | 46 | 48 | 47 | 141 |
| Current Tobacco Use(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Yes | 31 | 28 | 25 | 84 |
| No | 61 | 72 | 70 | 203 |
| Unknown or Not Recorded | 50 | 40 | 45 | 135 |
| Previous Alpha-blocker Use(participants) | Tadalafil 2.5 mg | Tadalafil 5 mg | Placebo | Total |
|---|---|---|---|---|
| Yes | 111 | 108 | 106 | 325 |
| No | 31 | 32 | 34 | 97 |
7 further baseline measures are reported on the registry.
The record gives a start of Nov 2008, a primary completion of Jun 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil